Curanex shares rise 10.48% intraday after successful IPO and $15 million fundraising.

Curanex Pharmaceuticals (CURX) surged 10.48% intraday following the announcement of its successful initial public offering (IPO) and subsequent exercise of the over-allotment option. The company priced its IPO at $4 per share on August 28, 2025, raising $15 million, and later secured an additional $2.25 million by fully exercising the over-allotment option on September 12, 2025. These developments signaled strong investor confidence in the biopharmaceutical company’s capital-raising capabilities and operational momentum, directly driving intraday buying activity. The positive sentiment around the expanded IPO proceeds aligned with the stock’s sharp intraday rally.